Global Research Trends

Friday 29 January 2021

Sucralfate Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

Sucralfate Market, by Formulation (Tablet and Liquid), by Indication (Gastric Ulcers, Duodenal Ulcers, Gastro Esophageal Reflux Disease (GERD), and Other Indications), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

Sucralfate is the generic form of the brand-name drug, Carafate. It is a prescription medicine used to treat ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to prevent reoccurrence of ulcers. Sucralfate is a hydroxy aluminum salt of sucrose octasulfate that functions as a local mucosal adherent. It forms a coating over ulcers by sticking to the affected area, which protects the area from acid and enzymes and helps ulcers to heal more quickly.

Sucralfate can also be used in treating ulcers and upper gastrointestinal disorders of dog, horse, and cat, which may arise due to drugs (particularly non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease, renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), and inflammatory bowel disease.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2325

Sucralfate Market Drivers

Increasing research and development activities for discovering new medicine using sucralfate is expected to propel growth of the sucralfate market. For instance, according to the American Broncho Esophagological Association report in April 2018, use of sucralfate along with honey aids in treatment of esophageal injury in infants and children. Esophageal injury in infants and children is associated with consumption of Button Batteries (BB), small disc-shaped batteries commonly found in toys. Use of sucralfate with honey can help in mitigation of the button batteries and allows symptomatic relief from esophageal injury.

Sucralfate Market Restraint

Drug shortages are projected to hinder growth of the sucralfate market. For instance, according to Drug Shortages Canada, report of September 2018, APO-SUCRALFATE - TAB 1G (APOTEX INC) that contained sucralfate was not available due to disruption in the manufacturing of the drug. The drug is used to treat peptic ulcer and gastro esophageal reflux disease (GERD).

Sucralfate Market – Regional Analysis

On the basis of region, the global sucralfate market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/sucralfate-market-2325

North America is expected to hold dominant position in the sucralfate market, owing to increasing number of clinical studies. For instance, University of Texas is conducting a clinical phase II study on sucralfate to improve oral intake in children with infectious oral ulcers. The study is expected to be completed by June 2019.

By 2026, Asia Pacific is expected to witness significant growth in the global sucralfate market due to increasing prevalence of H. pylori associated peptic ulcer disease, gastric cancer, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

Key players operating in the global sucralfate market include, SRL Pharma, Nitika Chemicals., Teva Pharmaceutical Industries Ltd., Lisapharma S.p.A, Aptalis Pharma US, Inc., Uniprix Group, Rx Outreach, Abcam Plc, and Quimica Alkano.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2325

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Fabry Disease Treatment Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Fabry Disease Treatment Market Regional Analysis

Europe Fabry disease treatment market is expected to witness a drastic growth over the forecast period, owing to penetration of key players in key regions of Europe with their novel products for Fabry disease. For instance, Amicus Therapeutics Inc. launched Galafold (Migalastat) for treatment of Fabry disease in Italy (in March 2017) and in Spain (in January 2018)

In November 2018, JCR Pharmaceuticals Co., Ltd, a Japan-based company launched biosimilar for agalsidase beta for treatment of Fabry disease. Launch of biosimilars is expected to increase affordability of these therapies in key regions of Asia Pacific as biosimilars are quite cheaper than biologics, hence it is expected to boost Asia Pacific Fabry disease treatment market growth.

Fabry disease also called as Anderson-Fabry disease and alpha-galactosidase-A deficiency is an X-linked, hereditary, lysosomal storage disease caused due to paucity of an enzyme α galactosidase A (an enzyme required to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids). The mutated gene leads the formation of lipids to harmful levels in various part of body such as the autonomic nervous system, cardiovascular system, eyes, and kidneys. Some of the common symptoms of this multisystem disorder include chronic pain, acroparesthesia, gastrointestinal disturbances, characteristic skin lesions (angiokeratomata), progressive renal impairment, cardiomyopathy, and stroke.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2326

Fabry Disease Treatment Market Drivers

In recent past, various regulatory bodies of key regions have approved novel medications for treatment of Fabry disease. Approval and launch of such novel medications in the region is expected to significantly support global Fabry disease treatment market growth over the forecast period.

For instance, in August 2018, Amicus Therapeutics, Inc., received the U.S. Food and Drug Administration (FDA) approval for its drug Galafold (migalastat). It is the first oral medication indicated for the treatment of adults with Fabry disease.

The presence of robust medication pipeline indicated for treatment of Fabry disease is also expected to be a major factor fueling growth of global Fabry disease treatment market over the forecast period. Table mentioned below represents list of some novel therapies in pipeline for Fabry disease treatment.

Furthermore, key players in the market are majorly investing in development of novel therapies for Fabry disease treatment, such strategic funding’s by various players is expected to drastically fuel global Fabry Disease treatment market growth over the forecast period. For instance, in February 2018, AvroBio Inc., closed US$ 60 million financing to support the phase 2 study of its novel gene therapy, AVR-RD-01 underdevelopment for the treatment of Fabry disease.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/fabry-disease-treatment-market-2326

Fabry Disease Treatment Market Restraint

Fabry disease is a very rare disease affecting around 1 individual in 50,000 (according to the National Fabry Disease Foundation), the diagnosis of Fabry disease is confirmed by demonstrating an enzyme deficiency in males and by identifying the specific GLA gene mutation in males and females.

Hence, low diagnostic rate due to unavailability of such diagnostic procedures and trained professionals in emerging economies such as Africa, India, and China are expected to be major factor restraining global Fabry disease treatment market growth.

Fabry Disease Treatment Market Key Players

Key players operating in global Fabry disease treatment market include: Amicus Therapeutics Inc., Sanofi Genzyme (Sanofi S.A. company), Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics, Inc., AvroBio Inc., JCR Pharmaceuticals Co., Ltd., Resverlogix Corp, and Ozmosis Research Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2326

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Hemodialysis and Peritoneal Dialysis Market Size Share Trends Forecast 2026

Hemodialysis and Peritoneal Dialysis Market Regional Analysis

North America Hemodialysis and Peritoneal Dialysis Market is expected to hold dominant position in the global market over the forecast period. Presence of leading manufacturers as well as increasing number of dialysis procedures is expected to support global hemodialysis and peritoneal dialysis market growth. According to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), over 661,000 people in the U.S. had kidney failure and of these, 468,000 individuals were on dialysis, 2017. These factors have supported the North America hemodialysis and peritoneal dialysis market growth.

Dialysis therapy includes hemodialysis to purify the blood using an artificial kidney (dialyzer) and peritoneal dialysis to purify the blood through one's own peritonea. There are two types of dialysis which are hemodialysis and peritoneal dialysis. Hemodialysis involves purification of the blood by removing waste products and extra fluid with the help of dialyzer membrane and the purified blood is returned into the body. Peritoneal dialysis involves purification of the blood by using the patient's own peritoneum as a dialysis membrane. Patients with chronic kidney diseases are generally kept on dialysis and normal kidney function can only be achieved through kidney transplantation.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2327

Hemodialysis and Peritoneal Dialysis Market Drivers

Global hemodialysis and peritoneal dialysis market growth is expected to be driver by innovative product launches by leading manufacturers, mergers and acquisitions, and initiatives by manufacturers to sustain and compete in global hemodialysis and peritoneal dialysis market. For instance, leading manufacturers such as Fresenius Medical Care AG & Co. KGaA are focusing on product launches as well as merger and acquisitions. Fresenius Medical Care supported the recommendation by the National Institute for Health and Care Excellence (NICE) to facilitate population healthcare management for UK patients with end-stage renal disease by using hemodiafiltration (HDF) rather than high-flux hemodialysis (HD) in October 2018. This is expected to boost global hemodialysis and peritoneal dialysis market growth over the forecast period.

Moreover, Fresenius Medical Care and Humacyte, Inc. entered into a strategic partnership in November 2018. Humacyte has developed HUMACYL, which is currently being investigated for vascular access for hemodialysis. Moreover, in April 2018, Fresenius Medical Care won the Red Dot Award: Product Design for the company’s 6008 CAREset bloodline system used in hemodialysis. Furthermore, Fresenius Medical Care signed an agreement to acquire NxStage Medical, Inc., (NxStage), a U.S.-based medical technology and Services Company in 2017. B. Braun Medical, Inc. signed an agreement to acquire the bloodlines business operated under the Medisystems name by NxStage Medical, Inc. In 2017 NxStage Medical, Inc. announced that the U.S. Food and Drug Administration (FDA) cleared its System One for solo home hemodialysis. These factors are expected to support global hemodialysis and peritoneal dialysis market growth over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/hemodialysis-and-peritoneal-dialysis-market-2327

Stringent regulatory policies for the approval and manufacturing, reimbursement, and risks and complications associated with dialysis treatment are expected to restrain global hemodialysis and peritoneal dialysis market growth over the forecast period.

Hemodialysis and Peritoneal Dialysis Market Key Players

Key players operating in the global hemodialysis and peritoneal dialysis market include Fresenius Medical Care AG & Co. KGaA, DaVita Healthcare Partners, Inc., Baxter International, Inc., B. Braun Melsungen AG, Nipro Corporation, Diaverum Deutschland GmbH, Nikkiso Co. Ltd., Asahi Kasei Corporation, and NxStage Medical, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2327

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Cardiac Rhythm Management Devices Market To Surpass US$ 35 Billion By 2026 - Coherent Market Insights

The Global Cardiac Rhythm Management Devices Market, by Product Type (Cardiac Resynchronization Therapy Devices, Defibrillator, and Pacemakers), by End User (Hospitals, Home Care Settings, and Ambulatory Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 19.05 billion in 2017, and is projected to exhibit a CAGR of 7.5% over the forecast period (2018 - 2026),.

Cardiac Rhythm Management (CRM) devices perform many functions, including monitoring for arrhythmias, bradycardia pacing, cardiac resynchronisation for heart failure, defibrillation and anti-tachycardia pacing for tachyarrhythmias. In the past few decades, use of cardiac rhythm management devices has increased worldwide due to increase in life expectancy and technological developments in products such as cardiac resynchronization therapy (CRT). Increasing consumption of caffeine is the most common factor linked with abnormal heart rhythms. Furthermore, excessive consumption of red wine can lead to symptoms of arrhythmias. Substances such as automobile emissions, cigarette smoke, pollution from industrial plants, paint thinners, and propane gas can also result into problems related to cardiac rhythms. However, high product price and infection risks associated with product implantation are the major concerns for manufacturers, as these are obstructing the product adoption. As per the study published by the National Cardiovascular Data Registry 2014, implantable cardioverter defibrillator infection rate has been reported to be around 1.7%. It is the third leading cause of complications occur due to CRM devices.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2364

According to a study published in Health Affairs, the average price for a dual-chamber pacemaker in Germany was US$ 1,400 in 2014 and in the U.S. it was US$ 4,200. Moreover, risks associated with product design is major concern for developers. In November 2018, Boston Scientific issued a hazard alert in Australia regarding its SQ-RX Model 1010 Pulse Generator in some of the first-generation subcutaneous implantable cardioverter defibrillator (S-ICD) systems. Future innovations in CRM products is expected to shift from transvenous leads to leadless designs with combinations of different components on a modular basis according to the function required. Moreover, CRM devices with remote controlling such as implantable cardioverter defibrillators and pacemakers can send information from the device to a portable unit, which allows the healthcare professional to monitor the patient condition at any time.

Browse 28 Market Data Tables and 24 Figures spread through 155 Pages and in-depth TOC on "Cardiac Rhythm Management Devices Market, by Product Type (Cardiac Resynchronization Therapy Devices, Defibrillator, and Pacemakers), by End User (Hospitals, Home Care Settings, and Ambulatory Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/cardiac-rhythm-management-devices-market-2364

Key Takeaways of the Cardiac Rhythm Management Devices Market:

The global cardiac rhythm management devices market is expected to expand at a CAGR of 7.5% during the forecast period (2018–2026), owing to increasing number of arrhythmias patients globally. According to the Center for Diseases Control and Prevention (CDC) 2017 data, an estimated 2.7 to 6.1 million people in the U.S. have heart arrhythmias.

Among region, Asia Pacific is expected to generate significant revenue in 2018, due to rising adoption of cardiac rhythm management devices in the region. According to the Heart, Lung and Circulation Journal 2015 study, around 20,000 cardiac rhythm management devices are implanted across Australia annually, around three-quarters of which are pacemakers.

Major players operating in the global cardiac rhythm management devices market include Medtronic plc., Abbott Laboratories, Abiomed, Boston Scientific Corporation, Biotronik Se Co Kg, Koninklijke Philips N.V., LivaNova Plc., Cardiac Science Corporation, Schiller Ag, and Zoll Medical Corporation

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2364

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Implantable Bioartificial Kidney Market Opportunity Analysis-2027

Implantable Bioartificial Kidney Market, by End User (Hospitals, Organ Transplant Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

An implantable bioartificial kidney is similar to existing extracorporeal renal assist device (RAD), which is a bioartificial kidney that combines a membrane hemofilter and a bioreactor to function as a healthy kidney. However, to work as a natural kidney, the bioartificial kidney should have high efficiency ultrafiltration membranes, should be able to regulate blood flow, and stabilize necessary cells. Implantable bioartificial kidney is capable of replicating the work of real kidney and can eliminate the need for dialysis. Implantable bioartificial kidney avoids constant physician oversight and need to take immunosuppressant drugs and medication.

Implantable Bioartificial Kidney Market: Drivers

Increasing number of chronic kidney disease patients, rising number of kidney failure incidences, and long waiting list for kidney transplants is expected to boost the global implantable bioartificial kidney market growth over the forecast period. For instance, according to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. Moreover, according to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2339

CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease. These factors are expected to drive the global implantable bioartificial kidney market growth over the forecast period.

Individual government organizations and manufacturers are working towards increasing the awareness of kidney diseases. For instance, American Kidney Fund (AKF) launched a comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). Moreover, The Kidney Project is a national research project, which aims to create a small, surgically implanted, and free-standing bioartificial kidney to treat end stage renal disease (ESRD). This kidney is expected to provide ESRD patients with a new option beyond the short-term solution of renal dialysis and the costly kidney transplant for which donor organs are limited.

Stringent regulatory policies for the approval and manufacturing, reimbursement, and risks and complications associated with dialysis treatment are expected to restrain the global implantable bioartificial kidney market growth over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/implantable-bioartificial-kidney-market-2339

Implantable Bioartificial Kidney Market: Regional Analysis

North America implantable bioartificial kidney market is expected to hold dominant position in the global market over the forecast period. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), over 661,000 people in the U.S. had kidney failure and of these, 468,000 individuals were on dialysis, in 2017. The kidney project, headed by researchers from the University of California San Francisco (UCSF), the University of Vanderbilt, and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), is expected to receive approval for the artificial kidney trials by late 2018 or early 2019. These factors are expected to support the North America implantable bioartificial kidney market growth over the forecast period. According to report of Brazilian Transplant Registry, 2016, Brazil accounts for the second largest number of kidney transplant programs in the world.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2339

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Thursday 28 January 2021

CpG Oligodeoxynucleotide Market Size, Share, Outlook, and Opportunity Analysis, 2020– 2027

CpG Oligodeoxynucleotide Market, by Source (Natural Source and Chemical Synthesis), by End User (Research Institutes, Hospitals, Contract Research Organizations, Pharmaceutical Companies, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

CpG oligodeoxynucleotide (CpG ODN) is a synthetic oligodeoxynucleotide, which contains unmethylated CpG motifs derived from bacterial DNA with immunostimulatory activities. CpG ODN is a short single-stranded synthetic DNA molecule, which contains one of each of cytosine triphosphate deoxynucleotide and guanine triphosphate deoxynucleotide that makes up the C component in the molecule.

The CpG motifs are considered pathogen-associated molecular patterns (PAMPs), as they are present in microbial genomes in abundance, but are rarely present in vertebrate genomes. These CpG PAMPs are recognized by the pattern recognition receptor (PRR) toll-like receptor 9 (TLR9), which is constitutively expressed only in B cells and plasmacytoid dendritic cells (pDCs) in humans and other higher primates. CpG ODNs show great potential for attachment in prophylactic vaccines designed to prevent infection. Various research companies are targeting synthetic CpG ODN due to the type I pro-inflammatory response it produces and its successful use as vaccine adjuvants.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2367

CpG Oligodeoxynucleotide Market – Dynamics

Increasing demand for vaccination across the globe is expected to contribute to significant growth of the CpG oligodeoxynucleotide market over the forecast period. For instance, according to the UNICEF-Vaccination & Immunization Statistics, in 2017, around 123 million children got immunized with lifesaving vaccines across the world. Moreover, according to the Centers for Disease Control and Prevention (CDC), at least 3,153,876,236 doses of vaccines were distributed in the U.S. from 2006 to 2016.

Rising prevalence of new chronic diseases and the demand for reducing the occurrence of childhood diseases such as polio and others are expected to propel growth of the CpG oligodeoxynucleotide market. According to the Centers for Disease Control and Prevention (CDC), around 25.3 per 100,000 children die at the age of 1-4 years due to congenital malformations, deformations, and chromosomal abnormalities, and others.

CpG Oligodeoxynucleotide Market – Regional Insights

On the basis of geography, the global CpG oligodeoxynucleotide market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America held dominant position in the global CpG oligodeoxynucleotide market in 2017. This is owing to high mortality due to various diseases such as pneumonia, diphtheria, pertussis, and others is expected to propel growth of the market in this region. For instance, according to the Centers for Disease Control & Prevention (CDC), in 2016, around 48,632 children died from pneumonia, which was around 15.1 per 100,000 population in the U.S.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/cpg-oligodeoxynucleotide-market-2367

Moreover, Asia pacific is expected to witness significant growth in the CpG oligodeoxynucleotide market, owing to rising focus on R&D along with mass manufacturing of cheap and affordable vaccines in the region. For instance, according to the International Vaccine Institute (IVI), India became the new hub for vaccine research with over 60% of the world’s vaccines manufactured in India in 2016.

CpG Oligodeoxynucleotide Market – Competitive Landscape

Major players operating in the global CpG oligodeoxynucleotide market include Novus Biologicals, InvivoGen, Merck KGaA, Hycult Biotech, Miltenyi Biotec, Sapphire Bioscience, Biomol GmbH, and Cosmobio. Key players are focused on adopting market strategies such as mergers and acquisitions, and new product development, in order to retain dominant position in the market. For instance, in July 2014, Techne Corporation acquired Novus Biologicals, a Colorado-based supplier of outsourced and in-house developed antibodies for life science research, for around US$ 60 million in cash.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2367

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Digital PCR and Real-time PCR (qPCR) Market Analysis-2027

Digital PCR and Real-time PCR (qPCR) Market: Regional Analysis

North America is expected to hold dominant position in the Digital PCR and Real-Time PCR Market, owing to increasing number of cancer cases, favoring the demand for PCR diagnostic tools and assays. According to a National Cancer Institute, 2016, an estimated 1,735,350 million new cases of cancer will be diagnosed in the U.S., with around 609,640 deaths from the disease in 2018. The number of people suffering from cancer is expected to rise to 19 million by 2024.

Polymer chain reaction (PCR) creates unlimited copies of DNA from a single strand using polymerase enzymes, primers, and multiple thermal cycles. PCR diagnostics are less prone to cross-contamination, as the procedure is conducted in automated thermal cyclers. dPCR and qPCR are common diagnostic techniques used in the research, pharma, and biotech institutes, and are widely used in variety of applications.

Real-time PCR allows specific and early disease diagnosis, allowing speedy and selective treatment for the patient. Also, PCR techniques have replaced the conventional infectious disease detection methods such as immunoassays as they are more specific and have become an integral part of laboratory diagnosis, thereby facilitating market growth.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2368

Digital PCR and Real-time PCR (qPCR) Market: Dynamics

Increasing adoption of qPCR in medical diagnosis to detect RNA viruses such as HIV and hepatitis C is expected to propel the market growth. According to the International Journal of Nanomedicine, 2017, around 36.7 million people were affected by human immunodeficiency virus (HIV) and around 400 million people were affected with viral hepatitis, globally. The survey also stated that with no reliable treatment for HIV infection, early diagnosis is a critical factor in managing AIDS patients, as it is a major cause for morbidity and mortality, globally.

Moreover, launch of technologically advanced products is expected to enhance the market growth. For instance, in November 2013, GNA Biosolutions GmbH launched an ultrafast PCR platform, Pharos V8 platform based on laser PCR. The platform uses nanomaterial to accelerate PCR reaction, by a factor of ten, thus making it suitable to be used in time-sensitive settings.

However, high device cost and adoption of alternative assays for disease detection and analysis is expected to hinder the market growth.

Digital PCR and Real-time PCR (qPCR) Market: Key Players

Key players operating in the global digital PCR and real-time PCR market include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Takara Bio, Inc., Danaher Corporation, Merck KGaA, Becton, Dickinson and Company, and Agilent Technologies, Inc.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/digital-pcr-and-real-time-pcr-qpcr-market-2368

Key development

In April 2019, Thermo Fisher Scientific Inc. introduced Applied Biosystems QuantStudio 6 and 7 Pro Real-Time PCR Systems, which includes new specifications like facial authentication, voice command and radiofrequency identification.

In January 2019, QIAGEN N.V. announced the development of range of next-generation systems for the digital polymerase chain reaction (digital PCR or dPCR) one of the fastest-growing molecular testing applications, which is expected to launch in 2020.

In 2017, Bio-Rad Laboratories, Inc. introduced iQ-Check Enterobacteriaceae real-time PCR detection kit that can be used for 94 samples.

In 2017, Agilent Technologies Inc. launched AriaDx Real-Time PCR System for Clinical Diagnostics in Europe to expand its molecular diagnostic portfolio.

In 2016, Danaher Corporation acquired Cepheid Inc. to expand its qPCR-product portfolio.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2368

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Mixed Reality in Healthcare Market Size Share Trends Forecast 2027

Mixed Reality in Healthcare Market - Regional Insights

On the basis of geography, Mixed Reality in Healthcare Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the mixed reality in healthcare market during the forecast period. The U.S. dominates the market in this region due to continuous technological advancements, and well developed healthcare infrastructure. Moreover, high adoption rate of technologically advanced products has fuelled growth of the market in this region.

Asia Pacific is expected to witness significant growth in the market during the forecast period, owing to rapid economic development and improvement of healthcare infrastructure along with rising disposable income of the people in the region. Moreover, increasing R&D and growing recognition of newer technologies in this region has driven growth for the mixed reality in healthcare market.

Mixed reality is a combination of both virtual reality (VR) and augmented reality (AR) by blending the real-life environment with digital elements. This is an emerging technology that has an enormous potential in the healthcare industry. Mixed reality continue to be a manageable force in the field of healthcare with various applications ranging from reducing the use of cadavers in medical student training to post-traumatic stress disorder (PTSD) engagement therapy for patients and pre-operative visualization of brain tumors by reviewing scans in-person using AR.

The implementation of mixed reality (MR) technologies in healthcare industry has improved the operational environment. MR technology uses AR for moving static images to improve an actual experience and VR engages the observer in a simulated 3D environment. Combination of IT solutions in healthcare field has brought transformational changes in the perception of patients’ treatment and services provided by healthcare providers.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2369

Mixed Reality in Healthcare Market - Market Dynamics

Growing demand for digitalization in healthcare sector is a major factor contributing to significant growth of mixed reality in healthcare market. Moreover, the market is expected to witness positive growth with rising prevalence of neurological & psychological disorders across the world. According to National Alliance on Mental Illness (NAMI) around 43.8 million, that is nearly 18.5% of the total adult population of the U.S., experienced mental illness in 2015, which is 1 in 5 adults in U.S. In addition, over 42 million American adults were suffering from anxiety disorders in 2015.

Moreover, rising awareness for use of MR technology in the applications of patient care management has supported growth of the market. For instance, the Autism Glass Project at Stanford University are developing a wearable behavioral aid that improves the verbal and non-verbal communication among patients. Autism glass application uses Google Glasses to identify facial expressions and give social indications that is linked to facial expressions.

However, lack of adequate skill among medical practitioners to adopt new technologies and high cost of some MR systems has restricted growth of the market. The price of a special equipment for the use of virtual reality in healthcare field starts with US$ 30,000 and could even exceed US$ 300,000.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/mixed-reality-in-healthcare-market-2369

Mixed Reality in Healthcare Market - Competitive Landscape

Key players operating in the mixed reality in healthcare market include Atheer, Augmedix, Daqri, Echopixel, Firsthand Technology, Medical Realities, Microsoft, Mindmaze, Oculus VR, Orca Health, Osso VR, Osterhout Design Group, Psious, Samsung Electronics, Start-Up Ecosystem, Surgical Theatre, and Widerun.

Growing technological development in the field of mixed reality encourages new companies in the healthcare industry to adopt proficient software-enabled solutions. Moreover, new product launches, rising funding for R&D, and mergers and acquisitions are some dynamic strategies opted by the prominent players to capture a reasonable amount of share and maintain its business presence in the global market. For instance,

In October 2018, Novarad received FDA 510(k) clearance for its Augmented Reality System - OpenSight Augmented Reality System. It is the first AR medical solution will be used in pre-operative surgical planning.

In November 2018, Precision OS received Series A funding worth US$ 2.3 million from AO Invest, for its virtual reality orthopedic surgical education and pre-operative planning software.

In January 2017, CAE Healthcare launched CAE VimedixAR, an ultrasound-training simulator, integrated with Microsoft HoloLens. This is the world’s first independent holographic computer. CAE Healthcare is the first company to bring a commercial Microsoft HoloLens application to the medical simulation segment.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2369

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Embolization Particle Market Size, Trends, Shares, Insights and Forecast – 2020-2027

Embolization Particle Market – Regional Insights

On the basis of geography, the global Embolization Particle Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America would be dominant region in the global embolization particle market in 2017. This is owing to the strong economic condition, huge expansion of healthcare domain, and increasing focus of research institutions on modernizing technology for new and advanced diagnosis and treatment methods. Moreover, unique hospital infrastructures, and availability of skilled healthcare professionals is further aiding growth of the market.

On the other hand, Asia Pacific is expected to witness significant growth in embolization particle market during the forecast period, owing to increasing patient population (mainly cancer) in emerging economies such as India. For instance, according to Indian Council Medical Research (ICMR), it is expected that over 17.3 lakh new cancer cases and over 8.8 lakh deaths will occur in India due to cancer by 2020. Moreover, growing focus by government on enhancing healthcare facilities and booming medical tourism is expected to boost growth of the embolization particle market in this region.

Embolization is a minimally invasive therapy in which an embolus is injected to stop bleeding or to cut off the supply of blood to a tumor in order to shrink it for preparation of its removal. Embolization is used in various interventional radiology procedures. In this procedure, an interventional radiologist uses image guidance to insert the catheter into a primary artery and advance it to vessel leading to a tumor or other part where the blood supply needs to be blocked. Embolization is an option for some patients with tumors that cannot be removed by surgery. It can be used for tumors that are usually larger than 5 cm thickness and cannot be removed by ablation. This procedure is used to treat various types of cancerous tumors, hemorrhages, along with the management of malignant hypertension caused by renal failure.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2374

Embolization procedure uses various types of embolization particles such as radioembolization spheres, microspheres, drug eluting beads, PVA particles, gelfoam particles, and other particles. These particles are used in different procedures such as liver cancer, metastatic cancer in the liver, kidney cancer, neuroendocrine tumors, uterine fibroids, and aneurysms. These particles are highly used in the treatment of various types of cancers whose prevalence has been increasing across the globe.

Embolization Particle Market - Market Dynamics

The market for embolization particle is driven by factors such as increasing prevalence of various types of cancer.

Embolization particles are the crucial product used in the treatment of malignancies such as cancer, peripheral diseases, and others. Rising prevalence of cancer globally, has supported growth of the embolization particle market. According to World Health Organization (WHO), cancer is the second prominent cause of death across the globe, and around 9.6 million deaths occurred due to cancer in 2018. Moreover, as per the Cancer Research UK, over 17 million new cases were estimated to occur in year 2018 around the globe. The burden of cancer is increasing rapidly in the U.S. with the incidence of 439.2 per 100,000 men and women per year as according to National Cancer Institute (2015).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/embolization-particle-market-2374

Moreover, major players are constantly introducing technologically advanced products with improved efficiency that supports growth of the embolization particle market. For instance, in 2017, Sirtex introduced SIR-Spheres Y-90 resin microspheres, which serves as first-line treatment for patients with liver metastases from right-sided primary colon cancer. In 2016, UK National Institute for Health and Care Excellence (NICE) issued a new update stating that National Health Service (NHS) doctors and commissioners may consider Sirtex’s SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer.

However, lesser number of interventional neuroradiologists and interventional neuroradiology (INR) labs across the globe and stringent regulations for embolization particle approvals are some of the major factors restraining growth of the global embolization particle market.

Embolization Particle Market – Competitive Landscape

Major players operating in the embolization particle markets include, Abbott Laboratories, Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Edwards Lifesciences, Johnson & Johnson, Pfizer, Inc., Sirtex Medical Limited, St. Jude Medical, Inc., and Terumo Corporation.

Key players are focusing on mergers & acquisitions and new product launches in order to retain dominant position in the market. For instance, in November 2018, Boston Scientific announced it plans to acquire BTG plc is a global healthcare company focused on interventional medicine. This will help the company to develop and commercialize products used in minimally-invasive procedures targeting cancer and vascular diseases

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2374

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Omeprazole Market To Surpass US$ 4.1 Billion By 2026 - Coherent Market Insights

Global Omeprazole Market, by Dosage Form (Capsule, Powder, and Tablet), by Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,668.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over the forecast period (2018 – 2026).

Launch of cost-effective generics by the market players to augment the market growth The global omeprazole market is expected to witness significant growth over the forecast period attributed to increasing incidence of gastric ulcers caused due to H.pylori infection and Nonsteroidal Anti-Inflammatory Drugs (NSAID) use. According to the study by Deccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70% of gastric ulcers are attributed due to Helicobacter pylori. Furthermore, the study also stated that around 14-25% of gastric and duodenal ulcers are associated with NSAID use. Furthermore, developers are focusing on approval and launch of cost-effective generic versions of omeprazole in order to enhance market sales. For instance, in July, 2017, Breckenridge Pharmaceutical, Inc. received the U.S. Food and Drug Administration (FDA) approval of abbreviated new drug application (ANDA) for Omeprazole delayed-release capsules. The drug will be manufactured and supplied by parent company- Laboratorios Dr. Esteve, S.A., Spain.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2380

Browse 22 Market Data Tables and 24 Figures spread through 138 Pages and in-depth TOC on “Omeprazole Market”- Global Forecast to 2026, by Dosage Form (Capsule, Powder, and Tablet), by Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder where the stomach acid enters esophagus, causing inflammation. The condition results in a long-lasting and serious from of acid reflux. According to the National Institute of Diabetes and Digestive and Kidney Diseases, 2014, an estimated 15.1 to 30 percent of the U.S. population is diagnosed with GERD. Moreover, According to the Department of Gastroenterology, Cedars-Sinai Medical Center, 2014, over nine million primary care visits in the U.S. are attributed to GERD annually, making it the most common gastroenterology-related outpatient diagnosis disease in the country. The market players are focused on developing treatment to offer heartburn relief by implementing innovative technologies. For instance, in April, 2018, Perrigo Company plc. and Dexcel Pharma Technologies, Ltd., launched Omeprazole delayed release orally disintegrating tablets (ODT) 20mg, with innovative MelTech melt-in-your-mouth technology for treating frequent heartburn. The innovative technology provides an affordable option in the OTC category.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380

Key Takeaways of the Omeprazole Market:

The global omeprazole market is expected to exhibit a CAGR of 5.2% over the forecast period, owing to increasing prevalence of peptic ulcer and acid related diseases and approval of generic versions by regulatory agencies. For instance, in 2016, Perrigo Company plc.received the U.S. FDA approval for omeprazole, thus launching a brand equivalent to Zegerid OTC capsules. Zegerid OTC is indicated for the treatment of frequent heartburn.

Among distribution channel, the online pharmacy segment is expected to holds a dominant position in the omeprazole market in 2026, owing to the higher amount of discount coupons granted for the generic and OTC omeprazole drugs

Some of the major players operating in the global omeprazole market include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc., Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2380

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Wednesday 27 January 2021

Osseointegration Implants Market Size Share Trends Forecast 2026

The Global Osseointegration Implants Market, by Product Type (Dental Implants, Knee Implants, Hip Implants, Spinal Implants and Others), By Material Type (Titanium Implants, Zirconia Implants, Stainless Steel Implants, Ceramic Implants, and Others), By End User (Hospitals, Ambulatory Centers, Dental and Orthopedic Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 5,672.3 million in 2017, and is projected to exhibit a CAGR of 6.72% over the forecast period (2018 - 2026).

Osseointegration implant is an endosteal implant that contain pores into which osteoblasts and supporting connective tissue can migrate. This implant is placed between living bone and surface of a load-bearing artificial implant. It is a fixation of alloplastic materials with a living part of patient for treatment purpose. Osseointegration implants has become a vital part of cosmetic dentistry industry due to the increasing the disposable income and increasing consciousness about the advanced technology among the patients and healthcare providers. Key players in osseointegration implants market are launching innovative products to generate a reasonable amount of share in the market. For instance, in June 2017, DePuy Synthes Companies launched Fenestrated Screw Systems- VIPER and EXPEDIUM in the U.S. market. These products would re-establish the correct posture of the spinal column in patients with advanced stage spinal tumors. Gradually increasing number of people suffering from edentulous is propelling demand for osseointegration implants. According to Indonesian Family Life Survey (IFLS), overall prevalence of edentulous was 7.2-29.8% in the age group >80 years and older in Indonesia in 2015. Furthermore, according to the report published by Public Health England, 2016, the highest prevalence of edentulous in England was around 17.8% in the age group of 65 to 74-years.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2384

Moreover, development of advanced technologies for dental implants and increasing number of dental practitioners are supporting growth of the osseointegration implants market. Increasing incidence of degenerative spinal conditions is another factor driving growth of the global osseointegration implants market. For instance, according to the National Spinal Cord Injury Statistical Center (NSCISC), 2017, around 17,500 new Spinal Cord Injury (SCI) cases are performed annually in the U.S. Moreover, an estimated amount of about 285,000 persons in the U.S. are living with SCI in 2017.

Browse 27 Market Data Tables and 24 Figures spread through 153 Pages and in-depth TOC on "Osseointegration Implants Market, by Product Type (Dental Implants, Knee Implants, Hip Implants, Spinal Implants and Others), By Material Type (Titanium Implants, Zirconia Implants, Stainless Steel Implants, Ceramic Implants and Others), By End User (Hospitals, Ambulatory Centers, Dental and Orthopedic Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

Key players in osseointegration implants market are adopting various strategies such as mergers, acquisitions, collaborations, and new product launch to maintain their position in the market and to gain a stronger foothold in the market. Moreover, a large number of companies investing in developing markets and distribution strategies has contributed to the transformation of medical sector in emerging economies. For instance, in January 2017, Integrum SE introduced the new OPRA Implant System Platform G which is used for transfemoral patients. This new system is CE labeled and approved by the FDA which has improved the mechanical performance of the system by simplifying the surgical procedure and enhancing osseointegration. The market in emerging economies is propelled by supportive government initiatives and growing awareness among the consumer as well as the healthcare providers for the use of osseointegration implants, and growing medical tourism in these regions. Furthermore, increasing consumption of unhealthy food and sedentary lifestyle has contributed to an increase disease prevalence, which have a positive impact on the growth of the osseointegration implants market. According to the World Health Organization (WHO), more than 1.9 billion adults were overweight and around 650 million people were obese worldwide in 2016.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/osseointegration-implants-market-2384

Key Takeaways of the Osseointegration Implants Market:

The global osseointegration implants market is expected to expand at a CAGR of 6.72% during the forecast period (2018–2026), owing to rising number of joint replacement surgeries. According to American Joint Replacement Registry (AJRR), in 2015, over 97, 673 primary hip replacement procedures and 87,593 primary knee replacement procedures were performed in the U.S.

Among product type, knee implants segment is expected to hold the major revenue share in 2018, owing to increasing incidence of osteoarthritis and rheumatoid arthritis among geriatric population

Among material type, ceramic implants segment is projected to have the highest CAGR during the forecast period, owing to its biocompatibility and aesthetic appearance.

Among end user, the hospital segment is expected to hold the major revenue share in 2018, owing to high rate of hospitalization due to rising number of joint replacement procedures

Major players operating in the global osseointegration implants market include Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, Southern Implants and ConMed Corporation.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2384

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737